Latest Developments in the Xarelto Litigation

Posted in Defective Drugs, Xarelto

Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people taking the medication since it entered the market.

Since its approval, there have been numerous reports of increased risk of injury when taking Xarelto, including, but not limited to:

  • Brain hemorrhage
  • Hemorrhagic stroke
  • Gastrointestinal bleeding

These events can be very serious and even life threatening since Xarelto is, by design, not monitored or regulated as closely as warfarin. Moreover, unlike warfarin, there is no antidote for Xarelto to stop uncontrolled bleeding.

Many of the pending lawsuits are centralized in federal court before the Honorable Eldon E. Fallon, in the Eastern District of Louisiana, as part of MDL 2592. Judge Fallon has entered a series of Case Management Orders that will maximize the efficient management of the litigation. The parties have agreed to case management tools that will make it easier to share information, file pleadings and communicate with the court. For example, the Court, along with the plaintiffs’ steering committee, has recently implemented a system known as MDL Centrality, which will enable plaintiffs to quickly share case-related information.

In addition, Judge Fallon recently held a “Science Day” to discuss and familiarize himself with relevant topics such as atrial fibrillation, coagulation and anticoagulation, clinical practice with Xarelto, adverse events with Xarelto and Xarelto pharmacology. These topics, among many others, were presented to the Court by physicians and scientists selected by counsel for both sides in the case.

The attorneys at Stark & Stark continue to pursue all legal redress available in the federal action, as well as state actions in Pennsylvania and New Jersey, for the benefit of its clients that have suffered injuries resulting from their use of Xarelto. If you feel you have experienced any side-effects from taking Xarelto, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Xarelto.

GlaxoSmithKline Seeks Consolidation of Zofran Lawsuits in Federal Court

Posted in Defective Drugs, Zofran

Zofran (ondansetron), manufactured by GlaxoSmithKline (GSK), is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran is commonly prescribed for use by pregnant women suffering from morning sickness. Studies show that Zofran use by pregnant women can lead to a heightened risk of severe birth defects, including heart development irregularities, cleft lip and cleft palate.

On July 6, 2015, GSK filed a motion with the Judicial Panel on Multidistrict Litigation requesting the court to consolidate all Zofran cases before one judge into a Multi-District Litigation (MDL). Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.

GSK argues that the United States District Court for the Eastern District of Pennsylvania, located in Philadelphia, PA, is the most convenient venue for the MDL.

If you or your child has suffered any injury as a result of taking Zofran, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Zofran manufacturers.

Zofran Studies Link Medication to Serious Health Risks

Posted in Defective Drugs, Zofran

Zofran (ondansetron), manufactured by GlaxoSmithKline (GSK), is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran is commonly prescribed for use by pregnant women suffering from morning sickness. Studies show that Zofran use by pregnant women can lead to a heightened risk of severe birth defects, including heart development irregularities, cleft lip and cleft palate.

A recent study by researchers at Harvard and Boston University’s Slone Epidemiology Center show that women exposed to Zofran, or a generic form of ondansetron, were 2.37 times more likely to deliver a baby with a cleft palate. These findings follow a series of epidemiological studies that have found an increased risk of major birth defects associated with exposure to Zofran during early pregnancy. For example, Swedish researchers, analyzing birth records from 1998 through 2012, concluded that “mothers who took Zofran during early pregnancy had a 62% increased risk of having a baby with a cardiovascular defect.”

If you or your child has suffered any injury as a result of taking Zofran, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Zofran manufacturers.

Jury Awards $100 million to Pelvic Mesh Patient

Posted in Transvaginal Mesh

The litigation against manufacturers of pelvic mesh devices continues to increase nationwide. A pelvic mesh implant is a synthetic material implanted and tied to ligaments or bone to lift and support internal organs. The implants were introduced over a decade ago, and can serve as an alternative to a hysterectomy. Thousands of women, who were allegedly uninformed about the dangers involved with the mesh implants, have since complained of injuries, including severe pain, infections and bleeding that often require follow-up surgeries.

A Delaware jury ordered Boston Scientific to pay $100 million to a woman that was injured by a pelvic mesh device. The trial took two weeks to finish. It took the jury only seven hours to conclude that Boston Scientific had negligently designed the devices and also failed to warn patients and doctors about potential risks. Many of the more than 70,000 pelvic mesh cases remain pending in federal court before U.S. District Judge Joseph Goodwin. Judge Goodwin continues to push the manufacturers to consider settling their cases.

If you or a loved one has experienced any injury from the use of a pelvic mesh implant, please contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against a manufacturer of the device.

Xarelto Litigation Continues to Grow

Posted in Defective Drugs, Xarelto

Xarelto (Rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011, to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people taking the medication since it entered the market.

Since its approval, there have been numerous reports of increased risk of injury when taking Xarelto, including, but not limited to:

  • Brain hemorrhage
  • Hemorrhagic stroke
  • Gastrointestinal bleeding

These events can be life threatening since, unlike warfarin, there is no antidote for Xarelto to stop the bleeding.

As we have previously reported, many of the pending lawsuits are centralized in federal court before the Honorable Eldon E. Fallon in the Eastern District of Louisiana as part of MDL 2592. In addition to these cases, the filing of Xarelto cases in state courts, such as Pennsylvania, continues to rise.

If you feel you have experienced any side-effects from taking Xarelto, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Xarelto manufacturers.

Zofran Litigation Continues to Grow Across the Country

Posted in Defective Drugs, Zofran

Zofran (ondansetron), manufactured by GlaxoSmithKline (GSK), is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran was approved by the Food and Drug Administration (FDA) in January 1991, to treat chemotherapy-related nausea, and the approval was later expanded to treat postoperative nausea and vomiting. Since then, it has been increasingly prescribed for off-label uses, such as use by pregnant women suffering from morning sickness. Studies show that Zofran use by pregnant women can lead to a heightened risk of severe birth defects, including heart development irregularities, cleft lip and cleft palate.

In 2012, GSK agreed to pay the United States Department of Justice $3 billion to settle numerous civil and criminal allegations, including the illegal marketing of Zofran. The company is now facing lawsuits filed on behalf of children born with heart defects or craniofacial birth defects because their mothers took Zofran during pregnancy.

If you or your child has suffered any injury as a result of taking Zofran, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Zofran manufacturers.

$3.6 Million Verdict in Actos Bladder Cancer Lawsuit

Posted in Actos

As we have previously reported, thousands of lawsuits have been filed against Takeda Pharmaceutical Company for its medication Actos after studies revealed that diabetics taking the drug may be at an increased risk of developing bladder cancer. In 2011, the U.S. Food and Drug Administration (FDA) warned that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.

A plaintiff, alleging Actos caused his bladder cancer, was recently awarded $2.3 million in compensatory damages by a jury in Pennsylvania state court. The jury found that Takeda showed “reckless indifference” to the plaintiff’s health by hiding Actos’ risks and awarded another $1.3 million in punitive damages. There are approximately 8,000 other similar lawsuits currently pending in federal and state courts across the country.

If you believe you have experienced adverse side-effects from taking Actos, contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

Zofran Injuries Continue To Be Reported

Posted in Zofran

Zofran (ondansetron), manufactured by GlaxoSmithKline, is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran was approved by the Food and Drug Administration (FDA) in January 1991, to treat chemotherapy-related nausea, and the approval was later expanded to treat postoperative nausea and vomiting.

According to recent allegations, it is believed that Zofran has also been marketed and prescribed for off-label uses, such as use by pregnant women suffering from morning sickness. According to a recent article published by the American Journal of Obstetrics & Gynecology, “Presently 97.7% of prescriptions for the treatment of nausea and vomiting in pregnancy in the United States are with medications not labeled for use in pregnancy, not indicated for nausea and vomiting in pregnancy, and not classified as safe in pregnancy by the Food and Drug Administration.”

Studies show that Zofran use by pregnant women can lead to a heightened risk of severe birth defects, including heart development irregularities, cleft lip and cleft palate.

If you feel you have experienced any side-effects from taking Zofran, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Zofran manufacturers.

Xarelto Cases Consolidated in New Orleans, Louisiana

Posted in Defective Drugs, Xarelto

The United States Judicial Panel on Multi-District Litigation (MDL) recently convened to determine whether the cases, known as IN RE: XARELTO (RIVAROXABAN)

PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.

The Judicial Panel granted MDL status and signed a Transfer Order on December 12, 2014. The cases will be consolidated and transferred to the Eastern District of Louisiana and presided over by the Honorable Eldon E. Fallon. The Judicial Panel decided the Eastern District of Louisiana was appropriate given the number of filings potential tag-along cases in that district and the fact that Judge Fallon is an experienced transferee judge with a willingness and ability to manage the litigation efficiently.

If you feel you have experienced any side-effects from taking Xarelto, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Xarelto manufacturers.

Xarelto Injuries Continue To Be Reported

Posted in Defective Drugs, Xarelto

Xarelto (Rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011, to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat).

Since its approval, there have been numerous reports of increased risk of injury when taking Xarelto, including, but not limited to:

  • Brain hemorrhage
  • Hemorrhagic stroke
  • Gastrointestinal bleeding

These events can be life threatening since, unlike warfarin, there is no antidote for Xarelto to stop the bleeding.

If you feel you have experienced any side-effects from taking Xarelto, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the Xarelto manufacturers.